Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells

• Published in: Anticancer research Vol. 19; no. 5B; p. 4131
• Main Authors: Nakata, A, Tsujimura, T, Sugihara, A, Okamura, H, Iwasaki, T, Shinkai, K, Iwata, N, Kakishita, E, Akedo, H, Terada, N
• Format: Journal Article
• Language: English
• Published: Greece 01.09.1999
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Bone Neoplasms - diagnostic imaging; Bone Neoplasms - pathology; Bone Neoplasms - prevention & control; Bone Neoplasms - secondary; Breast Neoplasms - pathology; Female; Humans; Interleukin-18 - administration & dosage; Interleukin-18 - pharmacology; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Osteoclasts - drug effects; Osteolysis - prevention & control; Radiography; Recombinant Proteins - pharmacology; Time Factors; Tumor Cells, Cultured
• ISSN: 0250-7005; 1791-7530

Effects of interleukin (IL)-18 on experimental bone metastasis of human breast cancer cells, MDA-231 cells, in nude mice were investigated. In addition, effects of IL-18 on subcutaneous growth of MDA-231 cells were examined. Bone metastasis was produced by an intracardiac injection of MDA-231 cells. Twenty eight days after the cell injection, severe osteolytic bone metastasis was examined by X-ray radiography, and both non-osteolytic and osteolytic bone metastases were examined microscopically. IL-18 (1 microgram/mouse) was injected intraperitoneally according to protocols A and B. In protocol A, IL-18 was injected daily from day 7 after an intracardiac or subcutaneous injection of cells, and in protocol B, it was injected daily for 7 days each before and after the cell injection. In protocol A, IL-18 injections significantly suppressed both the incidence of osteolytic bone metastasis detected by X-ray radiography (about 80% vs. about 20% for the control group vs. the treatment group) and the number of its foci/mouse (1.6 vs. 1 for the control group vs. the treatment group). However, they did not cause significant effects on either the incidence of bone metastasis detected microscopically or the number of its foci/mouse. In protocol B, IL-18 injections caused no significant effects on either the incidence of osteolytic bone metastasis detected by X-ray radiography or the number of its foci/mouse. They caused no significant effects on the incidence of bone metastasis detected microscopically, but significantly decreased the number of its foci/mouse (about 2.0 vs. about 1 for the control group vs. the treatment group). In both protocols A and B, IL-18 injections produced no significant effect on the tumor take and subsequent growth of tumors after a subcutaneous injection of the cancer cells. Since in protocol A, IL-18 appears to have exerted its action after establishment of metastasis by cancer cells to the bone marrow, the effects of IL-18 found in Protocol A indicate that IL-18 inhibited osteolytic growth at bone metastatic sites of breast cancers. On the other hand, since in protocol B IL-18 is likely to have functioned around the time when lodging of cancer cells and early development of metastasis occur in the bone marrow, the effects of IL-18 found in Protocol B indicate that the cytokine also suppresses an early stage of bone metastasis of breast cancers, although, this effect was less apparent than the effect on osteolytic growth. Therefore, IL-18 may be useful for suppression of osteolytic bone metastasis which is a serious problem in patients of advanced breast cancers.